Compare PXLW & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXLW | QTTB |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 44.3M |
| IPO Year | 2000 | N/A |
| Metric | PXLW | QTTB |
|---|---|---|
| Price | $5.70 | $4.35 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $14.33 | $7.33 |
| AVG Volume (30 Days) | 63.8K | ★ 179.9K |
| Earning Date | 03-12-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,205,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.67 | $1.35 |
| 52 Week High | $15.42 | $6.37 |
| Indicator | PXLW | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 35.63 | 60.19 |
| Support Level | $5.77 | $3.42 |
| Resistance Level | $6.08 | $4.70 |
| Average True Range (ATR) | 0.37 | 0.42 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 17.27 | 69.53 |
Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company operates in one segment: the design, development, marketing and sale of IC solutions for use in electronic display devices. The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.